Literature DB >> 12932379

Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?

Gordon D O Lowe1, Peter A G Sandercock, Frits R Rosendaal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932379     DOI: 10.1016/S0140-6736(03)14149-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.

Authors:  Giancarlo Agnelli; Giorgio Bolis; Lorenzo Capussotti; Roberto Mario Scarpa; Francesco Tonelli; Erminio Bonizzoni; Marco Moia; Fabio Parazzini; Romina Rossi; Francesco Sonaglia; Bettina Valarani; Carlo Bianchini; Gualberto Gussoni
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

2.  Low-molecular-weight heparins: before or after surgery? New concepts and evidence: Congress report from the Sigma Tau/ROVI Satellite Symposium (Rome, Italy, 13 November 2006).

Authors:  Eduardo Rocha; Davide Imberti; Elio Paschina
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 3.  Management of venous thromboembolism in the elderly.

Authors:  Alex C Spyropoulos; Geno Merli
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery.

Authors:  David Bergqvist
Journal:  Vasc Health Risk Manag       Date:  2006

Review 5.  Thrombo-prophylaxis in acutely ill medical and critically ill patients.

Authors:  Saurabh Saigal; Jai Prakash Sharma; Rajnish Joshi; Dinesh Kumar Singh
Journal:  Indian J Crit Care Med       Date:  2014-06

6.  Thromboprophylactic Efficacy and Safety of Anticoagulants After Arthroscopic Knee Surgery: A Systematic Review and Meta-Analysis.

Authors:  Yang Yu; Shitao Lu; Jinpeng Sun; Wei Zhou; Hongjian Liu
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.